Differential 3-year effects of first- versus second-generation antipsychotics on subjective well-being in schizophrenia using marginal structural models

Journal of Clinical Psychopharmacology

Volumn 31, Issue 2, 2011, Pages 226-230

  Lambert, Martin ^a   Schimmelmann, Benno G ^b   Schacht, Alexander ^c   Suarez, David ^d   Haro, Josep Maria ^d   Novick, Diego ^e   Wagner, Thomas ^c   Wehmeier, Peter M ^c,f   Huber, Christian G ^a   Hundemer, Hans Peter ^c   Dittmann, Ralf W ^f   Naber, Dieter ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^c LILLY DEUTSCHLAND GMBH   (Germany)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^e ELI LILLY AND COMPANY   (United States)

^f UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

antipsychotics; marginal structural model; quality of life; schizophrenia; subjective well being

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERAZINE; QUETIAPINE; RISPERIDONE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MARGINAL STRUCTURAL MODEL; MATHEMATICAL MODEL; NEUROLEPTIC TREATMENT SCALE; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; POST HOC ANALYSIS; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; QUALITY OF LIFE; SCHIZOPHRENIA; TARDIVE DYSKINESIA; WELLBEING;

ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PATIENT SATISFACTION; PROSPECTIVE STUDIES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 79952438099     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3182114d21     Document Type: Article

References (16)

1. Lambert M, Naber D. Current issues in schizophrenia: overview of patient acceptability, functioning capacity and quality of life. CNS Drugs. 2004;18(suppl 2):5-17. (Pubitemid 38858281)
2. Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 2006;63:1079-1087. (Pubitemid 44498387)
3. Voruganti L, Cortese L, Oyewumi L, et al. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr Res. 2000;43:135-145. (Pubitemid 30386882)
4. Naber D, Moritz S, Lambert M, et al. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr Res. 2001;50:79-88. (Pubitemid 32510889)
5. Angermeyer MC, Holzinger A, Kilian R, et al. Quality of lifeVas defined by schizophrenic patients and psychiatrists. Int J Soc Psychiatry. 2001;47:34-42. (Pubitemid 32573879)
6. Haro JM, Salvador-Carulla L. The SOHO (Schizophrenia Outpatient Health Outcome) study: implications for the treatment of schizophrenia. CNS Drugs. 2006;20:293-301.
7. APA. Diagnostic Criteria From DSM-IV. Washington, DC: American Psychiatric Publishing; 1994.
8. Lambert M, Schimmelmann BG, Naber D, et al. Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia. J Clin Psychiatry. 2006;67:1690-1697. (Pubitemid 44955148)
9. Karow A, Moritz S, Lambert M, et al. PANSS syndromes and quality of life in schizophrenia. Psychopathology. 2005;38:320-326. (Pubitemid 43074271)
10. Wehmeier PM, Kluge M, Schacht A, et al. Correlation of physician and patient rated quality of life during antipsychotic treatment in outpatients with schizophrenia. Schizophr Res. 2007;91:178-186.
11. Haro JM, Kamath SA, Ochoa S, et al. The Clinical Global ImpressionYSchizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand Suppl. 2003;16-23.
12. Robinson DG, Woerner MG, Alvir JM, et al. Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophr Res. 2002;57:209-219. (Pubitemid 35240023)
13. Robins JM, Hernán MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11:550-560. (Pubitemid 30660034)
14. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17:2265-2281. (Pubitemid 28466823)
15. Cramer JA, Rosenheck R, Xu W, et al. Quality of life in schizophrenia: a comparison of instruments. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Schizophr Bull. 2000;26:659-666.
16. Ritsner MS, Gibel A. The effectiveness and predictors of response to antipsychotic agents to treat impaired quality of life in schizophrenia: a 12-month naturalistic follow-up study with implications for confounding factors, antidepressants, anxiolytics, and mood stabilizers. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30:1442-1452. (Pubitemid 44634956)